Linked Life Data

3390053

Source:http://linkedlifedata.com/resource/pubmed/id/3390053

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1988-8-4
pubmed:abstractText
A prospective, double-masked, randomized study evaluated the effects of unilateral therapy with topical 1% apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145) in 20 normal volunteers. No medications were applied to either eye during the control day. Following baseline measurements on the day of treatment, one drop of topical 1% apraclonidine hydrochloride was placed on one eye and a placebo (vehicle) was placed on the fellow eye. Intraocular pressure (IOP) measurements, pupil size, blood pressure, and pulse rate were assessed on both days at the baseline and 1, 3, 5, and 7 hours later. The 1% apraclonidine hydrochloride lowered the mean IOP (+/- SD) a maximum of 6.5 +/- 4.3 mm Hg (37.3% +/- 20.4%) from the baseline on the day of treatment. A statistically significant 2.7 +/- 3.4-mm Hg (14.9% +/- 19.0%) mean IOP decrease from the baseline was noted in the contralateral placebo-treated eye. No significant changes in the coefficient of outflow, blood pressure, or heart rate were noted. Eyelid retraction, conjunctival blanching, and mydriasis were frequently noted in eyes treated with 1% apraclonidine hydrochloride.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0003-9950
pubmed:author
pubmed:issnType
Print
pubmed:volume
106
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
912-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Short-term effects of unilateral 1% apraclonidine therapy.
pubmed:affiliation
Glaucoma Services, Sinai Hospital of Baltimore, MD.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't